How Would Artificial Pancreas Tech Impact Afrezza Sales?

[mnkdnewbie]

NVO sec doc 10/11/2016

[brentie]

i believe that this is what mnkdnewbie is referring to...


www.thepharmaletter.com/article/fda-delays-us-approval-of-novo-nordisk-s-faster-acting-insulin-aspart-issuing-a-crl

[madog365]

Even if it NVO approved, Afrezza will be one of two options for the Artifical Pancreas of today. And that's according to Dr. Kowalski, not me.  


Since there are multiple other pump companies also developing these hybrid systems besides MDT, MNKD can sign a co-marketing agreement with some type of rev share. I believe this type of deal could be quite lucrative for Mannkind.

[mnholdem]

I just posted a link to the Insulin Nation article, not realizing it had already been mentioned here. You're right about Afrezza being the perfect fit for Medtronic's new 670G, since this "artificial pancreas" still requires mealtime boluses.  The article states that the insulin available in the market is not fast-absorbing enough to work with the pump (obviously he's speaking of injectable insulin).

I have sent a suggestion to management that they consider marketing that idea. Strike while the iron is hot! Marketing needs to better utilize the news of these developments to continually help build brand awareness within the medical diabetes treatment industry!

 

mnkd.proboards.com/thread/6510/why-bolus-first-artificial-pancreas 

[madog365]

The important part of this article is the email update from Dr.Kowalski where he specifically mentions Afrezza as one of two options (and the only currently approved one) 

I would think Mannkind already has something in the works and will be ready to announce soon. My prediction is it will be a co-marketing with insulet or dexcom based on the study they were a part of. Right now only MDT system is approved but insulet has one in the pipeline as well. 



clinicaltrials.gov/ct2/show/NCT01874392

Drug: Investigational inhaled insulin (Technosphere)

by MannKind Corp. IND 61,729

Other Name: Technosphere® Insulin Inhalation System (Gen2C inhaler)

Device: Artificial Pancreas (AP) device (APS©)

Device includes:



OneTouch® Ping® Glucose Management System with modified Meter-Remote from Animas® Corp or the OmniPod® Insulin Management System from Insulet Corp.

Dexcom® G4® CGM System (CGM) from Dexcom® Corp

Control algorithm: zone-Model Predictive Control (zone-MPC) with safety Health Monitoring System (HMS)

Other Name: Artificial Pancreas System platform (APS©) from the University of California, Santa Barbara and SDRI

[Deleted]

Oct 20, 2016 9:04:19 GMT -5 madog365 said:

The important part of this article is the email update from Dr.Kowalski where he specifically mentions Afrezza as one of two options (and the only currently approved one) 

I would think Mannkind already has something in the works and will be ready to announce soon. My prediction is it will be a co-marketing with insulet or dexcom based on the study they were a part of. Right now only MDT system is approved but insulet has one in the pipeline as well. 



clinicaltrials.gov/ct2/show/NCT01874392

Drug: Investigational inhaled insulin (Technosphere)

by MannKind Corp. IND 61,729

Other Name: Technosphere® Insulin Inhalation System (Gen2C inhaler)

Device: Artificial Pancreas (AP) device (APS©)

Device includes:



OneTouch® Ping® Glucose Management System with modified Meter-Remote from Animas® Corp or the OmniPod® Insulin Management System from Insulet Corp.

Dexcom® G4® CGM System (CGM) from Dexcom® Corp

Control algorithm: zone-Model Predictive Control (zone-MPC) with safety Health Monitoring System (HMS)

Other Name: Artificial Pancreas System platform (APS©) from the University of California, Santa Barbara and SDRI

the study was already done and there is a youtube video of it

Principal Investigator: Howard Zisser, MD William Sansum Diabetes Center

[madog365]

Yes, but Insulet then purchased the algorithm, partnered with Dexcom and is currently running a new study in order to get this system approved for commercialization. You can see the study below, it is brand new.

clinicaltrials.gov/ct2/show/NCT02897557?term=omnipod&rank=5


Also interesting. Howard Zisser the main contact on this study was recently hired by Verily to develop their AP. 

[madog365]

Used google translate on this article from JDRF - www.jdrf.nl/inhaleerbare-insuline-afrezza-opnieuw-op-markt-gebracht/

January 23, 2017

last line of the article: JDRF is investigating the possibilities to combine Afrezza with an artificial pancreas, which Afrezza is used for meal bolus and the artificial pancreas (eg Medtronic 670g) keeps blood glucose levels stable beyond.

Interesting? Maybe, Maybe not.

[madog365]

Interesting mention in yesterday's call regarding Afrezza for AP.

"The final trial that we're interested in watching is the Yale study. It's a closed loop system looking at the artificial pancreas. We've heard from several investigators that the best way for the artificial pancreas to function and have a tight range of control, is by adding Afrezza, which speaks to our speed of action. This trial we expect to start in the next few weeks."